Enterprise Value

861.6M

Cash

157.9M

Avg Qtr Burn

-14.49M

Short % of Float

18.22%

Insider Ownership

21.35%

Institutional Own.

64.70%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
YUTREPIA (Treprostinil) (LIQ861) Details
Rare diseases, Pulmonary arterial hypertension, Lung disease, Pulmonary hypertension associated with interstitial lung disease

Approved

Update

YUTREPIA (Treprostinil) (LIQ861) Details
Pulmonary arterial hypertension, Lung disease, Pulmonary hypertension associated with interstitial lung disease, Rare diseases

Big Mover™

Susp. Mover™

PDUFA

Approval decision

L606 Details
Pulmonary hypertension associated with interstitial lung disease, Pulmonary arterial hypertension

Phase 3

Data readout

LIQ865 Details
Post-surgical pain

Failed

Discontinued